• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability

    2020-10-22 04:30:58AnujBohraQuratAlAinRizviCharlotteYuenYuKeungAbhinavVasudevanDanielvanLangenberg
    World Journal of Gastroenterology 2020年36期
    關(guān)鍵詞:大伙

    Anuj Bohra, Qurat-Al-Ain Rizvi, Charlotte Yuen Yu Keung, Abhinav Vasudevan, Daniel R van Langenberg

    Abstract

    Key Words: Inflammatory bowel disease; Infliximab; Safety; Cost; Therapy; Drug reaction

    INTRODUCTION

    Infliximab is a biologic monoclonal IgG antibody against tumour necrosis alpha (anti-TNF). It is a highly effective induction and maintenance treatment for multiple immune-mediated inflammatory disorders, including inflammatory bowel diseases (IBD)[1-3]. Recently in Australia and many countries worldwide, the accessibility of infliximab for indications within IBD has increased, alongside an increasing trend to use accelerated doses and shorter dose intervals to regain and/or achieve remission in certain disease subtypes[4,5]. Hence, despite a growing number of biologic options, many of which are subcutaneously administered, there has still been an increased demand for infliximab infusions over recent years. As a maintenance therapy, infliximab (and other infusion-based biologic agents) are often prescribed on a longterm basis[6-8]. Allocation of funding to resource-intensive infusion centres may not always a priority for hospital administrators, given the traditional hospital model of care is typically focussed on acute inpatient care resulting in continual pressure on infusion centres already at, or near capacity. Additionally, the cost of infusion-based treatment is expensive, with some studies suggesting that the cost of the administering infliximab is approximately 9% to 12% of the total cost of treatment[9,10].

    In an effort to address these capacity and cost issues for infusion centres shortening the infusion time is one potential solution. Rapid infliximab infusions (at typically 30-60 min’ duration per infusion) have been previously identified in IBD and other indications as safe, with the potential for increased capacity yet reduce cost, plus apparently improve patient satisfaction[9,11]. Despite this, with the recent further exponential growth of infusion-based therapies for various chronic diseases, improving efficiencies within infusion centres does not appear sufficient and there is still an imperative to explore further alternatives.

    Home-based infusions are therefore a logical extension from hospital or infusioncentre based infusions and are potentially appealing to both patients and health providers. Home-based infusions of many drug therapies have been demonstrated to be cost-saving and are used in many jurisdictions worldwide[12,13]. However, homebased infliximab poses a challenge given the relatively high rate of infusion reactions, including anaphylaxis and anaphylactoid reactions[14,15], the need to dilute and refrigerate the medication and the two hours required for the infusion and one hour observation period thereafter[16]. Some of these problems can be overcome to allow patients to have their infusions at home. For example, initial therapy can be completed in the hospital to monitor for any reactions and then subsequent infusions can be administered at home. Rapid infusions and home-based infusions of infliximab are currently undertaken at our hospital. The safety of this approach is yet to be comprehensively evaluated. Therefore, we aimed to evaluate the safety of transition from standard hospital-based infliximab infusions to rapid infusions and thence to home-based infusions in a protocolised manner, while also assessing efficiency, cost savings and patient satisfaction with this process.

    MATERIALS AND METHODS

    Patient selection and data collection

    All consecutive patients with confirmed IBD attending two Australian tertiary inflammatory bowel disease centres over a 12-year period from January 2005 to March 2017 who were prescribed infliximab and commenced infusions at the study centres were identifiedviaan IBD database and/or pharmacy dispensing records, then prospectively followed. Inpatients receiving infliximab (for example for acute severe colitis) were excluded from this analysis. All patients underwent standard dosing of infliximab 5 mg per kilogram of body weight for induction at week 0, 2 and 6 followed by maintenance infusions, where dosing/dosage interval may have been altered as per the treating clinician’s discretion, predominantly to address secondary loss of response.

    Data including baseline demographic data, IBD data including disease distribution duration and complications, therapeutic data including adverse drug reactions (ADRs) and location of infliximab administration, were extracted from medical records. The severity of infliximab infusion reactions were graded retrospectively according to the Common Toxicity Criteria (CTC) version 2.0[17]from 1 to 4, with a CTC score of 1-2 graded arbitrarily defined as “mild” and 3-4 as “severe” reactions respectively.

    Inclusion criteria:(1) Aged 18 and above; and (2) Received maintenance therapy infliximab between January 2005 and March 2017 for an IBD indication.

    Exclusion criteria:(1) Less than age 18; (2) Received infliximab for a non – IBD indication; and (3) received infliximab as an inpatient.

    Study outcome measures

    The primary outcome measure in this study was the safety of infliximab infusions, with the standard infusion protocol as per manufacturer’s guidelines as the reference, compared to (1) a rapid infusion protocol; and (2) a rapid infusion protocol administeredviaa home-based service, comparing relative incidence of serious adverse events. Secondary outcomes assessed included the relative cost of infusion centre and home-based infliximab infusions and factors associated with a higher risk of infusion reactions in order to risk stratify patients prior to referral for home-based infusions.

    Initial standard 2-h infusion data was available from patients infused between January 1, 2005 to December 31, 2013, inclusive. Rapid 30-min infliximab infusion data was available from patients infused between January 1, 2014 and March 31, 2017 inclusive and home-based rapid infliximab infusion data was available from patients infused between October 1, 2017 and December 31, 2019 inclusive. In each case, needle to departure times were collected for each patient for time spent in at an infusion centre and compared between the standard and rapid infusion groups.

    Cost analysis

    Moreover, a cost analysis was performed for infusion centre and home-based delivery of infliximab, comprising study centre staff costs (per unit time) and infusion-related consumables (per unit), per infusion. Total infusion time duration was measured from time of cannula insertion to the patient’s time of departure from the infusion centre, or the time of the nurse’s departure from the home setting (i.e., needle to departure time), given these events were accurately recorded in the medical records for all patients.

    Satisfaction and productivity survey relating to rapid/ home-based infusions

    Patients who were transitioned to home-based infusions were asked to complete a survey comprising items assessing their satisfaction regarding rapid infusions compared to standard infusions and rapid infusions administered in infusion centrebasedvshome-based settings (see Appendix). The items included were customised based on feedbackviaqualitative interviews of a subgroup of rapid infusion patients (by investigators DvL and QaR), given no suitable, previously validated surveys were found in the literature. Responses to each item were recorded across a numerical scale from 1 (most negative) to 5 (most positive) with 3 denoted as neutral. Furthermore, the short IBD Questionnaire (sIBDQ), to measure concurrent health-related quality of life and the Work Productivity and Activity Impairment in IBD Questionnaire (WPAIIBD) were also administered to examine perceived effects of rapid infliximab infusions (including home-based) on these domains[18]. Based on the cut-off derived by Swartet al[19], a sIBDQ score of greater than 55 (total 70 indicating excellent quality of life) was deemed to represent a “satisfactory/normal” quality of life[19,20]. Loss of work productivity and daily activity impairment (expressed as a percentage, 100% indicating complete loss/impairment) were derived from the WPAI-IBD as per Reillyet al[20]. The surveys were applied to a seven-day period including a home-based infliximab infusion.

    Infliximab infusion protocols used

    The rapid infusion protocol as applied is shown in Figure 1. Patients underwent their first 3 infusionsviaa standard 2-h infusion protocol, then progressed onto an “accelerated” 1-h infusion for infusion 4-6 if there were no adverse reactions and from the 7thinfusion onwards then received “rapid” infusions over 30 min thereafter assuming no further reactions. ADRs were treated immediately according to severity and only those graded as mild-moderate had a subsequent re-trial of infliximab at the last tolerated infusion rate. A standardised pre-medication regimen of 200 mg intravenous hydrocortisone, 10 mg oral cetirizine and 1 g oral paracetamol was administered to all patients prior to their first three standard infusions and also immediately in the case of ADRs, as per the nursing and/or medical staff’s discretion at the time.

    Subsequently, those who tolerated at least three rapid infusions without ADRs were offered the opportunity to transition their infusion to home-based infusions. Patients with known active psychiatric comorbidities, unsafe (i.e., for visiting nursing staff) or itinerant living conditions and/or previous poor adherence to medications, infusion and/or clinic visits were deemed unsuitable candidates for home-based infusions and were not offered this option.

    Ethics approval

    The Eastern Health Human Research Ethics Committee approved the study as a low risk audit (LR 64/2017), thus informed consent was deemed not required.

    Statistical analysis

    Figure 1 Rapid infliximab infusion protocol. BP: Blood pressure; IV: Intravenous; IFX: Infliximab.

    Comparisons between the infusion groups were performed using non-parametric statistics (assuming non-normal distributions) with medians (ranges) presented and Mann-Whitney tests calculated where appropriate. Proportions were expressed as percentages and compared using Fisher exact tests, including relative risks (RR) of infusion reactions/ADRs which were presented for both per infusion and per patient.

    In order to determine factors potentially associated with the occurrence of one or more infusion reaction(s) to rapid infliximab infusion(s), univariable analyses [expressed as odds ratios (OR) for categorical variables, with 95% confidence intervals displayed] were performed. Then a multivariable logistic regression analysis was conducted with the occurrence of an infusion reaction(s) due to rapid infusion as the dependent variable. Multiple exploratory models were initially undertaken and forced entry models were always used, with the final model chosen on the basis of effect size and goodness of fit of the overall model. All variables with significant or those trending to significance were included in the multivariable analysis plus other putatively important factors were included, such as age and body mass index (BMI) (dichotomised by cut-off < 22 kg/m2representing the lowest quartile in this cohort). Those factors exerting minimal or no effect size within the model (as per standardised B values) were excluded from the final model. APvalue of < 0.05 was deemed to be statistically significant throughout the study.

    RESULTS

    Baseline demographics

    The standard infusion cohort comprised 169 patients who received a total of 2214 infliximab infusions over an 8-year period (2006 to 2013 inclusive) and the rapid infusion cohort comprised 129 patients who received a total of 1461 infusions over a 4-year period (2014-2017 inclusive). Home-based rapid infusions were administered to 32 patients, with a total of 405 infusions over 2.2 years (October 2017 to December 2019 inclusive). The baseline characteristics of the standard and rapid infusion cohorts are represented in Table 1.

    Infliximab infusion ADRs and outcome of rechallenges in standard vs rapid infusion cohorts

    In the standard infusion cohort, a total of 23 patients experienced ADRs directly related to infliximab infusion(s), with 16 of these graded as mild according to CTC. All 16 patients were rechallenged with infliximab of which 15 tolerated the subsequent infusion with the aid of premedications and a slower infusion rate. Seven patients had severe reactions and were not rechallenged.

    In the rapid infusion cohort, 8 patients experienced ADRs due to infliximab, all ofwhich (8/8) were mild as per the CTC. Of these, 7 patients were rechallenged with concurrent premedications administered and all seven tolerated the subsequent infusion; four patients returned to rapid infusions, two remained on accelerated infusions and one returned to the standard infusion protocol. All of the eight patients described had previously documented ADRs to standard protocol infusions.

    Table 1 Baseline characteristics comparing the standard infusion (n = 169) and rapid infusion (n = 129) cohorts

    Hence per infliximab infusion administered, the relative risk (RR) for a mild reaction was 0.8% and 0.7% and for a severe reaction was 0.2% and 0.0% in the standard infusion and rapid infusion cohorts respectively. Per patient, the overall RR for a mild reaction was 10.7% and 7.8% and for a severe reaction 3.0% and 0.0% within the standard and rapid infusion cohorts respectively, as shown in Table 2.

    Moreover, there was a greater likelihood of patients having an infusion reaction (mild or severe) in the standard protocol cohort than patients receiving rapid protocol infusions, RR 3.0, 95%CI (1.2, 7.7),P= 0.02. The median duration from the commencement of infliximab and the first infusion reaction per patient was 17 d (0, 1401) for standard infusions and 637 d (45, 2122) for rapid infusions respectively.

    Factors associated with increased risk of infliximab infusion reactions in this cohort

    A univariable logistic regression analysis was performed on all patients in the cohort who received three or more infliximab infusionsviathe rapid infusion protocol. Factors found to be significantly associated (P< 0.05) and/or trending to significance (0.05 ≤P≤ 0.15) with the occurrence(s) of infliximab ADR/s were then included into a multivariable logistic regression analysis, as shown in Table 3. In summary, a lower BMI (< 22 kg/m2), history of one or more extra intestinal manifestations, longer disease duration (> 3 years) and previous exposure to another biologic were each independently associated with a higher likelihood of infusion reaction(s) to rapid infusions (eachP< 0.05). There was a non-significant trend to a higher risk also with prior episodic and/or a break in maintenance infliximab dosing.

    再說的時候,就說到找一陣了,還是找不到。找不到,摟寶的就直起身,說剛才你們看到了,是萬子吧?他們說,有紅有黑的,應(yīng)該是吧。見大伙認帳,摟寶的跟了句,是八萬吧?這句話,大伙不認帳了。就那么一閃,誰也看不清呀。他想想,也是,那怎么辦呀?大伙說,再找找吧,找到了,我們給錢的,不賴帳的。這次,大伙還幫他找了。找到最后,也沒找到。

    Table 2 Infusion reactions per cohort, type and severity

    Comparison of infusion time/cost and productivity (standard vs rapid infusion cohort)

    Median needle to departure time was significantly higher in the standard protocol than the rapid protocol group [108 (70, 253)vs50 (33, 90) min,P< 0.001] (Figure 2). Based on local costing and consumables, this equated to a median per infusion (per chair) cost of $AUD 49.80 per rapidvs$107.50 per standard protocol infusion (P< 0.001). Hence since inception, rapid infusion protocols resulted in a net cost saving of $AUD 84344 (a net 54% cost reduction) across the whole study centre cohort and follow-up period.

    Transition from infusion centre to home-based rapid infusions: Safety and cost analysis

    The baseline characteristics of the rapid home and rapid infusion centrecohorts are represented in Table 4. 32 patients were transitioned to home-based infusions havingreceived at least three rapid infusions in hospital infusion centres with no history of infusion reaction/s to rapid infusions. In total, 405 infliximab infusions had hitherto been administeredviathe home-based service as of the end of the study follow-up period, with no (0%) reported ADRs. Six patients who subsequently withdrew from the home-based infusion service were due to personal choice (n= 3), change to a different biologic (n= 2) or death (n= 1, unrelated to IBD and/or associated therapies).

    Table 3 Univariable and multivariable logistic regression analyses depicting factors potentially associated with increased likelihood of infliximab infusion reaction/s with a rapid infusion protocol in this cohort (n = 129)

    Table 4 Characteristics of home-based vs infusion centre-based rapid protocol groups

    Moreover, there was no significant difference in needle to departure times between infusion centre and home-based rapid infusions [median 50 (33, 90)vs45 (31, 90) min respectively,P= 0.21] (Figure 2). In turn, there were similar costs (incorporating staffing and consumables) between these groups (median $49.80vs$39.20 per infusion,P= 0.20).

    Figure 2 Needle-to-departure times for standard vs rapid (further subdivided by infusion centre and home based) infliximab protocols.

    Patient satisfaction with home-based infusions: Data from survey

    Of the 32 patients who received infliximabviathe home-based infusion service, 31 (97% response rate) completed the survey as described. 26 of the 31 were in clinical remission as per CDAI < 150 at the time of survey and the median sIBDQ score in responders was 55 (33, 65) with 57% scoring in the “normal” IBD QoL range as per Swartet al[19].

    Only 2 patients (6.4%) reported that their infliximab infusions had a negative impact on their quality of life overall. All 31 (100%) patients preferred the rapid infusionvsthe standard infusion protocol, with 17 patients (54.8%) specifically stating this was due to enhanced convenience (Figure 3).

    14 of the 31 responders (45.2%) disagreed with or were neutral about a preference for home-basedvsinfusion centre-based infusions and 19 (61.3%) found home-based infusions to actually be more inconvenient than those administered in an infusion centre (Figure 3).

    Qualitatively, reasons provided for this included a lack of coordination and communication of the timing of infusions, unforeseen delays in nurse arrival at their home, lack of nursing staff (e.g., due to illness or extra demand) on certain days forcing patients to attend the parent hospital for their infusion(s), lack of sufficiently skilled nurses resulting in difficulties obtaining intravenous access and/or administering infusion at slower rates than prescribed. Additionally, others reported a reluctance to “medicalise” their home and/or have infusions in presence of family members (especially their children) or work colleagues. Also, some patients missed the familiarity of the same nursing staff and the camaraderie enabled by attending the same infusion centre, as many had done, for several years.

    Impact of home-based infusions on work productivity/activity as per survey

    Responses from the WPAI-IBD showed that in the week including when infliximab was infused at home, there was a median of 0 h per week missed from paid work (range 0, 36.7 h), with only 4 (12.9%) reporting a total of one or more hours of work missed in the same week. Also, the median overall work impairment (incorporating both percentage of work hours missed and impairment of work performance) was 10.0% (0, 81.0).

    DISCUSSION

    Figure 3 Results of patient satisfaction survey and preferences regarding standard vs rapid and infusion centre vs home-based infusions.

    This study has demonstrated the safety of rapid 30-min infliximab infusions compared to standard 2-h infusions in patients with IBD. Moreover, by applying a rational stepwise protocol as per Figure 1 culminating in almost 1500 rapid infusions, none of these resulted in severe reactions. Furthermore, of the 8 patients who had mild reaction, 7 were able undertake a re-trial of infliximab on premedication with 6 successfully transitioning back to 30-min rapid infusions. These safety data are consistent with similar protocolised rapid infliximab studies previously[9,21,22], yet are critical to confidently administering infliximab infusions in home-based settings. Otherwise, without stringent protocols, infliximab infusion reactions have been reported in up to 5%-10% of infusions in IBD[15,23], which in our view does not provide adequate assurance of safety for home-based infliximab. Indeed, in this cohort, none of the home-based infusions experienced an adverse reaction as a result of this study centre’s stepwise protocol introducing rapid infusions prior to transitioning to the home.

    In addition, this study is one of the first to elucidate factors associated with a higher risk of adverse reactions with maintenance rapid 30-min infusions, which enables clinicians to further mitigate the risk of adverse reactions on a case-by-case basis. Although infusion reactions to initial infliximab infusions (e.g., with induction or with episodic dosing) are typically attributable to allergic or massive cytokine release pathways, longer term reactions are postulated to be driven primarily by the development of immunogenicity (i.e., antibodies) to infliximab[24]. Accordingly, this study demonstrated that a longer disease duration (> 3 years) was associated with a higher risk of reaction(s), consistent with the known cumulative incidence of antibodies to infliximab in prospective studies[25]. Also, those with prior biologic exposure and/or a break in previous infliximab dosing were found, at least in univariate analysis, to be at higher risk of reaction(s) as has been shown elsewhere[26]. Furthermore, the presence of extraintestinal manifestations, suggestive of a more systemic inflammatory burden and in turn a greater propensity for immunogenicity – for instance due to presence of alternate cytokine-mediated, immune-complex and/or complement mediated processes – appears to be another important risk factor with rapid infusion reactions. Although there was a non-significant trend in univariable analysis to a protective effect of concomitant thiopurine/immunomodulator therapy on infusion reactions, presumably due to their negating effect on antibody development, this did not persist in multivariable analysis. Interestingly, a lower BMI (< 22 kg/m2) was associated with increased risk of rapid infusion reaction(s) despite recent publications showing increased drug clearance and lower anti-TNF drug trough levels seen with higher BMI[27,28]. However, a lower BMI with resultant reduced volume of distribution may in fact result in relatively higher infliximab trough levels and hence greater potential for immunogenicity and thus acute and delayed ADRs. Infliximab drug levels and anti-drug antibodies were not routinely performed in this cohort, so further study into the potential relationship between these factors are needed.

    One of the key benefits of transitioning to 30-min infliximab infusions is that of reduced cost and enhanced productivity for an infusion centre. With introduction of rapid infusions, we demonstrated a halving of needle to departure times per infusion in a real-world context, with attendant cost reduction of 54% across the whole cohort. At an institutional level, this enables a potential doubling of throughput with the same staffing costs for an infusion centre. For the patient and at a societal level, there are additional flow-on benefits such as reduced car parking costs, reduced absence from work and/or family commitments through to improved patient productivity.

    Given the increasing array of intravenous therapies, including infliximab, for chronic diseases leading to infusion centre capacity concerns in many jurisdictions worldwide, transitioning to home-based infusions is a logical solution. However, to ensure the economic sustainability of home-based infusion service, nurses theoretically need to conduct at least 3-4 infusions at patients’ homes per standard 8-h shift, allowing for travel between homes, preparation of infusions and intravenous access, communication with patients,etc. Hence administering infliximab slower than over 30 min is unlikely to be cost-effective in most cases. This study has demonstrated the safe, sustainable administration of infliximab in a home-based setting, subject to appropriate patient selection. Furthermore, this study is one of the first to assess patient satisfaction which overall was high, with 81% highly satisfied or satisfied with home-based infusions. In addition, survey responders reported minimal impact on work or other activitiesviathe WPAI during a typical week that included a homebased infliximab infusion.

    However, the study also revealed previously un-appreciated caveats to implementation of home-based infusions from the patients’ perspective. Almost half of the survey responders were neutral or disagreed that home-based infusions were more convenient, anecdotally for reasons including unforeseen delays to nurse arrival, variable availability of staff to administer infusions, impacts on work and social life and medicalising their home with infusions. These are unintended consequences of transitioning to home-based infusions and pose potential challenges to this model of care which therefore warrant further research and evaluation.

    This study has several limitations, including the retrospective nature of data collection, however the risk of recall bias is somewhat mitigated given this study was primarily an evaluation of protocol and safety in a relatively consistent, homogeneous single centre population. Although the sample size for rapid and standard infusion cohorts were relatively large, the home-based infusion subgroup was small which may have led to selection bias and larger scale evaluation of the latter is required in future. Furthermore, given the large time period across which data was collected and local contemporary practice, we were unable to evaluate the putative relationship between infliximab trough/antibody levels and occurrence of infusion reactions. There was a difference in the rate of psychiatric disorders between the groups. While this is unlikely to have an impact on the results it does reflect that there may be some differences between the groups that was not captured in our demographic data. Prospective validation of the results is required.

    CONCLUSION

    In conclusion, this study comprehensively outlines a safe, patient centred approach to transitioning patients receiving infliximab for IBD from initial standard protocols through to rapid home-based infusions. With careful patient selection, we have demonstrated that the risk of ADRs with home-based infusions is negligible and thus these data are reassuring to patients, clinicians and healthcare providers alike. Whilst there are significant logistical challenges in providing a failsafe, home-based infusion service and ongoing evaluation especially in meeting patient’s care needs is warranted in this regard, most patients were satisfied with this service and the convenience it provides. This study has therefore defined a rigorous framework for the safe, potentially cost saving delivery of not only infliximab but potentially other similar medical infusions at home.

    ARTICLE HIGHLIGHTS

    Research background

    Infliximab is one of the most commonly used biologic therapies in the management of inflammatory bowel disease (IBD). With the development of infliximab biosimilars and resulting reduction in medication cost, its availability and usage worldwide has seen exponential growth for all therapeutic indications.

    Research motivation

    Previous studies have suggested rapid 30 min infliximab infusions to be safe in patients with IBD. Despite this, few centres have moved to deliver infliximab therapy for IBD at a patient’s home and there remains a paucity of literature demonstrating the cost benefit of rapid infliximab infusion compared to standard therapy.

    Research objectives

    The primary aims in this study were to evaluate the safety of transition from standard hospital-based infliximab infusions to rapid infusions and thence to home-based infusions in a protocolised manner, while also assessing efficiency, cost savings and patient satisfaction with this process.

    Research methods

    This retrospective study was conducted across two tertiary IBD centres in Australia. Based on pharmacy prescribing records and historic IBD databases, patients who received infliximab over a 12-year period were identified. Data related to infliximab therapy was retrospectively obtained. Patients that were transitioned to at home infliximab were prospectively surveyed for satisfaction and productivity.

    Research results

    Our study reinforced previous findings in showing that rapid 30 min infliximab was safe in patients IBD with minimal side effects. Furthermore, with careful patient selection patients receiving rapid infusion infliximab were able to be safely transitioned to home based therapy. Rapid infliximab infusions resulted in the halving of time patients spent receiving an infusion and resulted in a 54% reduction in delivery related costs. Patients found the transition to rapid infliximab to be highly satisfying but were neutral about receiving infliximab therapy at home.

    Research conclusions

    In our study, rapid 30 min infliximab infusions appeared to be safe and in a protocolised manner could be delivered safely at home. This process has the ability to substantially reduce costs related to delivery of therapy and provides a viable alternative to under resourced infusion centres in the delivery of infusion therapy.

    Research perspectives

    Rapid Infliximab therapy can be delivered safely at home under the supervision of trained health care staff. Our study provides a framework for other centres to selectively transition patients from traditional infusion centres to alternative destinations such as home based. With further safety studies other infusion therapies could potentially be transitioned safety to be delivered at home at the convenience of the patient.

    猜你喜歡
    大伙
    巨大的回報
    哪里哪里?
    太陽感冒了
    老人的尊嚴
    上海故事(2018年4期)2018-07-09 18:44:58
    改啰唆
    愛你(2017年20期)2017-11-24 16:26:38
    冬天是個調(diào)皮的孩子
    官員講大白話,大伙愛聽
    紅土地(2016年11期)2017-01-15 13:46:36
    腳下生風(fēng)的磊編
    意林(2015年20期)2015-10-21 11:21:08
    生日福利
    趕時間的后果
    解放軍生活(2013年9期)2013-04-29 08:52:02
    国产精品日韩av在线免费观看| 又大又爽又粗| 久久久久久久精品吃奶| 天天添夜夜摸| 久久久久久大精品| 视频区欧美日本亚洲| 18禁黄网站禁片午夜丰满| 人人妻人人澡欧美一区二区| 日韩成人在线观看一区二区三区| 亚洲欧美日韩无卡精品| 欧美另类亚洲清纯唯美| 久久午夜综合久久蜜桃| 国产成人精品无人区| 搡老妇女老女人老熟妇| 免费看美女性在线毛片视频| 欧美性猛交黑人性爽| 宅男免费午夜| 在线观看www视频免费| 身体一侧抽搐| 日日夜夜操网爽| 亚洲七黄色美女视频| 欧美黑人巨大hd| 国产伦人伦偷精品视频| 亚洲成人精品中文字幕电影| 国产一区二区在线观看日韩 | 少妇的丰满在线观看| 亚洲国产中文字幕在线视频| 长腿黑丝高跟| 国产三级黄色录像| 亚洲乱码一区二区免费版| 国产三级在线视频| 2021天堂中文幕一二区在线观| 999久久久精品免费观看国产| 人妻夜夜爽99麻豆av| 精品久久久久久久人妻蜜臀av| 黄色毛片三级朝国网站| 国产成人欧美在线观看| 亚洲欧美激情综合另类| 啪啪无遮挡十八禁网站| 91国产中文字幕| 丰满人妻一区二区三区视频av | av片东京热男人的天堂| 一级作爱视频免费观看| 久久精品综合一区二区三区| 国产成年人精品一区二区| 日韩欧美一区二区三区在线观看| 国产欧美日韩一区二区三| 久久久久亚洲av毛片大全| 欧美在线黄色| 国产精品1区2区在线观看.| 女同久久另类99精品国产91| 一边摸一边做爽爽视频免费| 欧美高清成人免费视频www| 亚洲国产精品合色在线| svipshipincom国产片| 在线看三级毛片| cao死你这个sao货| 青草久久国产| 后天国语完整版免费观看| 国产精品久久视频播放| 一进一出抽搐动态| 1024手机看黄色片| 亚洲欧美精品综合久久99| 99久久综合精品五月天人人| 亚洲人成网站高清观看| 男女那种视频在线观看| 午夜精品一区二区三区免费看| 欧美 亚洲 国产 日韩一| 真人做人爱边吃奶动态| 亚洲成人免费电影在线观看| 国产男靠女视频免费网站| 国产精品一区二区精品视频观看| 亚洲电影在线观看av| av天堂在线播放| 国产三级在线视频| 久久精品影院6| 欧美性猛交黑人性爽| cao死你这个sao货| 制服诱惑二区| 午夜福利视频1000在线观看| 99久久国产精品久久久| 亚洲人与动物交配视频| 久久久久精品国产欧美久久久| xxx96com| 成年免费大片在线观看| 黑人欧美特级aaaaaa片| 精品国产乱子伦一区二区三区| 色综合欧美亚洲国产小说| 亚洲精品av麻豆狂野| 亚洲午夜精品一区,二区,三区| 悠悠久久av| 手机成人av网站| 不卡一级毛片| 欧美av亚洲av综合av国产av| 国产av一区二区精品久久| 日韩成人在线观看一区二区三区| 精品乱码久久久久久99久播| 久久天堂一区二区三区四区| 欧美日韩亚洲综合一区二区三区_| 久久久久久九九精品二区国产 | 最近最新免费中文字幕在线| 天堂动漫精品| 国产亚洲精品久久久久5区| 九九热线精品视视频播放| 岛国在线免费视频观看| 国产精品久久视频播放| 97人妻精品一区二区三区麻豆| 精品国产美女av久久久久小说| 亚洲狠狠婷婷综合久久图片| 麻豆国产97在线/欧美 | 亚洲精品中文字幕一二三四区| 亚洲熟妇熟女久久| av超薄肉色丝袜交足视频| 中文字幕人妻丝袜一区二区| 一级片免费观看大全| 制服诱惑二区| 久99久视频精品免费| 亚洲国产精品久久男人天堂| av片东京热男人的天堂| 日本三级黄在线观看| 别揉我奶头~嗯~啊~动态视频| 久久久久精品国产欧美久久久| 欧美高清成人免费视频www| 国产免费男女视频| 我的老师免费观看完整版| 一二三四在线观看免费中文在| 婷婷精品国产亚洲av在线| 国内精品一区二区在线观看| 精品人妻1区二区| 一二三四社区在线视频社区8| 99国产精品一区二区蜜桃av| aaaaa片日本免费| 男女那种视频在线观看| 亚洲va日本ⅴa欧美va伊人久久| 国产99白浆流出| 国产人伦9x9x在线观看| 日韩国内少妇激情av| 亚洲全国av大片| 日韩欧美 国产精品| 久久久久久久久久黄片| 黄频高清免费视频| 99riav亚洲国产免费| 别揉我奶头~嗯~啊~动态视频| 日本免费a在线| 久久久国产成人免费| 国产成人精品久久二区二区91| 两人在一起打扑克的视频| 在线观看免费午夜福利视频| 国产精品久久电影中文字幕| 国产午夜精品论理片| 人妻夜夜爽99麻豆av| 久久精品国产亚洲av香蕉五月| 国产高清视频在线观看网站| 国产精品久久视频播放| 欧美3d第一页| 久久精品国产综合久久久| 动漫黄色视频在线观看| 亚洲国产看品久久| 国产一区二区在线av高清观看| 男女视频在线观看网站免费 | 在线观看舔阴道视频| 久久精品国产综合久久久| 黄色成人免费大全| 在线观看免费视频日本深夜| 国内揄拍国产精品人妻在线| 亚洲av美国av| 国产成人影院久久av| 露出奶头的视频| 女警被强在线播放| 在线观看午夜福利视频| x7x7x7水蜜桃| 少妇的丰满在线观看| 看黄色毛片网站| 又紧又爽又黄一区二区| 国产伦在线观看视频一区| 日韩欧美国产一区二区入口| 午夜福利高清视频| 久久久水蜜桃国产精品网| 久久九九热精品免费| 高清在线国产一区| 曰老女人黄片| 亚洲 国产 在线| 每晚都被弄得嗷嗷叫到高潮| 亚洲精品美女久久久久99蜜臀| 亚洲男人天堂网一区| 国产亚洲av嫩草精品影院| 精品久久久久久成人av| 久久精品国产99精品国产亚洲性色| 一本综合久久免费| 欧美+亚洲+日韩+国产| 我的老师免费观看完整版| 免费高清视频大片| 88av欧美| 两性夫妻黄色片| 日韩欧美在线二视频| 精品无人区乱码1区二区| 淫妇啪啪啪对白视频| 国产视频一区二区在线看| 男女那种视频在线观看| 日本黄色视频三级网站网址| 又黄又爽又免费观看的视频| 97人妻精品一区二区三区麻豆| 亚洲18禁久久av| 国产精品九九99| 99在线视频只有这里精品首页| 国产探花在线观看一区二区| 国产亚洲精品一区二区www| 国产蜜桃级精品一区二区三区| 最近最新中文字幕大全免费视频| 叶爱在线成人免费视频播放| 可以免费在线观看a视频的电影网站| 国产伦一二天堂av在线观看| 在线国产一区二区在线| 国产精品综合久久久久久久免费| 免费在线观看视频国产中文字幕亚洲| 成人三级黄色视频| 国产黄a三级三级三级人| 久久久国产欧美日韩av| 国产伦人伦偷精品视频| 黄色视频不卡| 欧美人与性动交α欧美精品济南到| 亚洲人与动物交配视频| 午夜精品一区二区三区免费看| 国产精品一区二区三区四区免费观看 | 免费看日本二区| 中文字幕最新亚洲高清| 又紧又爽又黄一区二区| 色在线成人网| 丁香欧美五月| 人成视频在线观看免费观看| 一个人观看的视频www高清免费观看 | 亚洲美女视频黄频| 久久天躁狠狠躁夜夜2o2o| www.熟女人妻精品国产| 国产精品99久久99久久久不卡| 国产不卡一卡二| 日本 欧美在线| 99精品久久久久人妻精品| 老司机福利观看| 成人高潮视频无遮挡免费网站| 国产爱豆传媒在线观看 | 久久精品国产99精品国产亚洲性色| 又黄又粗又硬又大视频| 五月伊人婷婷丁香| 99久久无色码亚洲精品果冻| 国产成人一区二区三区免费视频网站| 韩国av一区二区三区四区| 亚洲乱码一区二区免费版| 欧美性猛交黑人性爽| 女人被狂操c到高潮| 亚洲国产精品合色在线| av国产免费在线观看| 国产亚洲欧美在线一区二区| 女警被强在线播放| 看黄色毛片网站| 久久久久亚洲av毛片大全| 久久人妻福利社区极品人妻图片| 欧美中文日本在线观看视频| 久久 成人 亚洲| 人人妻人人澡欧美一区二区| 少妇裸体淫交视频免费看高清 | 免费在线观看日本一区| 91字幕亚洲| 国产一区在线观看成人免费| 一个人观看的视频www高清免费观看 | 一a级毛片在线观看| 亚洲国产欧美一区二区综合| 九色国产91popny在线| 亚洲中文字幕日韩| 天堂√8在线中文| 国产欧美日韩一区二区精品| 亚洲免费av在线视频| 日韩精品中文字幕看吧| 国产精品av视频在线免费观看| 精品久久久久久久末码| 精品无人区乱码1区二区| 手机成人av网站| 亚洲18禁久久av| 国产日本99.免费观看| 国产精品电影一区二区三区| 久久国产乱子伦精品免费另类| 久久亚洲真实| 久久热在线av| 波多野结衣巨乳人妻| 午夜影院日韩av| 亚洲激情在线av| 制服诱惑二区| 亚洲午夜理论影院| 99re在线观看精品视频| 91成年电影在线观看| 欧美另类亚洲清纯唯美| 亚洲中文字幕一区二区三区有码在线看 | 老司机深夜福利视频在线观看| 97碰自拍视频| 欧美性猛交╳xxx乱大交人| 国产视频内射| 欧美激情久久久久久爽电影| 久久精品夜夜夜夜夜久久蜜豆 | 国产成人aa在线观看| 又黄又粗又硬又大视频| 免费在线观看影片大全网站| a级毛片a级免费在线| 亚洲人与动物交配视频| 日韩国内少妇激情av| 久久婷婷人人爽人人干人人爱| 一个人观看的视频www高清免费观看 | 黄色女人牲交| 午夜免费激情av| 国内精品久久久久精免费| 国产亚洲精品第一综合不卡| 俄罗斯特黄特色一大片| 午夜久久久久精精品| 少妇熟女aⅴ在线视频| 丰满人妻一区二区三区视频av | 每晚都被弄得嗷嗷叫到高潮| 制服丝袜大香蕉在线| 亚洲第一欧美日韩一区二区三区| 亚洲av成人一区二区三| 啦啦啦免费观看视频1| 免费在线观看完整版高清| 中国美女看黄片| 波多野结衣巨乳人妻| 国产精品98久久久久久宅男小说| 免费高清视频大片| 国产精品亚洲av一区麻豆| 亚洲 欧美一区二区三区| 亚洲欧美精品综合一区二区三区| 国产欧美日韩一区二区三| 热99re8久久精品国产| 国产精品野战在线观看| 在线观看舔阴道视频| 91麻豆精品激情在线观看国产| 国产精品爽爽va在线观看网站| 亚洲男人的天堂狠狠| 久久婷婷成人综合色麻豆| 最好的美女福利视频网| 男女床上黄色一级片免费看| 美女扒开内裤让男人捅视频| 国产精品电影一区二区三区| 一级a爱片免费观看的视频| 国产91精品成人一区二区三区| 三级毛片av免费| 九色国产91popny在线| 亚洲欧美日韩无卡精品| 一区福利在线观看| 99久久国产精品久久久| 久久久久国产一级毛片高清牌| 一边摸一边做爽爽视频免费| 亚洲精品美女久久av网站| 久9热在线精品视频| 在线国产一区二区在线| 两个人免费观看高清视频| 搡老妇女老女人老熟妇| 中文字幕久久专区| 国产精品98久久久久久宅男小说| 亚洲性夜色夜夜综合| 国产日本99.免费观看| 日本成人三级电影网站| 十八禁网站免费在线| 成人18禁在线播放| 欧美三级亚洲精品| 极品教师在线免费播放| 亚洲一区高清亚洲精品| 国产亚洲精品久久久久久毛片| 一二三四社区在线视频社区8| 老司机福利观看| 麻豆成人av在线观看| 欧美性猛交╳xxx乱大交人| 国产亚洲精品久久久久5区| 99热这里只有是精品50| 国产激情欧美一区二区| 婷婷六月久久综合丁香| 三级毛片av免费| 99国产精品99久久久久| 久久久国产欧美日韩av| 青草久久国产| 狂野欧美激情性xxxx| 免费在线观看影片大全网站| 91av网站免费观看| 成人18禁高潮啪啪吃奶动态图| 少妇人妻一区二区三区视频| cao死你这个sao货| 亚洲av成人一区二区三| 成人三级黄色视频| 免费在线观看黄色视频的| 精品国内亚洲2022精品成人| 两个人免费观看高清视频| 亚洲av成人av| √禁漫天堂资源中文www| 国产伦在线观看视频一区| 床上黄色一级片| www.www免费av| 无限看片的www在线观看| 免费av毛片视频| 久久久国产成人免费| 欧美精品亚洲一区二区| 国产主播在线观看一区二区| 国产精品亚洲av一区麻豆| 搡老熟女国产l中国老女人| 亚洲精品美女久久久久99蜜臀| 国产精品av久久久久免费| 国内精品久久久久精免费| 变态另类成人亚洲欧美熟女| 日韩三级视频一区二区三区| 欧美成人免费av一区二区三区| 国产精品98久久久久久宅男小说| 18禁美女被吸乳视频| 中文在线观看免费www的网站 | 久久中文字幕一级| 成人欧美大片| 国产一区在线观看成人免费| 欧美日韩福利视频一区二区| 精品少妇一区二区三区视频日本电影| 精品久久久久久,| 可以在线观看的亚洲视频| 欧美最黄视频在线播放免费| 国产精品久久久人人做人人爽| 亚洲av电影在线进入| 精品日产1卡2卡| 日韩欧美精品v在线| 亚洲av成人av| 欧美大码av| 欧美日韩黄片免| 免费看十八禁软件| 无限看片的www在线观看| 12—13女人毛片做爰片一| 日本免费a在线| 国产av一区在线观看免费| 欧美在线黄色| 一本久久中文字幕| 精品福利观看| 搡老妇女老女人老熟妇| 欧美丝袜亚洲另类 | 日本一区二区免费在线视频| 动漫黄色视频在线观看| 亚洲国产精品成人综合色| 日日爽夜夜爽网站| 中文字幕人成人乱码亚洲影| 免费在线观看成人毛片| 免费在线观看影片大全网站| 欧美中文综合在线视频| 国产男靠女视频免费网站| 18禁裸乳无遮挡免费网站照片| 国产亚洲精品一区二区www| 九色成人免费人妻av| 两个人看的免费小视频| 国产精品av视频在线免费观看| 少妇的丰满在线观看| 大型黄色视频在线免费观看| 制服诱惑二区| 久久久国产成人免费| 两个人的视频大全免费| 这个男人来自地球电影免费观看| 国产精品乱码一区二三区的特点| 亚洲精品一区av在线观看| 久久久国产成人免费| 夜夜看夜夜爽夜夜摸| 国产av不卡久久| 国产成人av激情在线播放| 黄片小视频在线播放| www.精华液| 午夜久久久久精精品| 日韩欧美一区二区三区在线观看| 欧美成人免费av一区二区三区| 国产真人三级小视频在线观看| 国产日本99.免费观看| 在线国产一区二区在线| 亚洲av日韩精品久久久久久密| 亚洲中文日韩欧美视频| 五月玫瑰六月丁香| 色av中文字幕| 日韩 欧美 亚洲 中文字幕| 国产精品亚洲av一区麻豆| 国产野战对白在线观看| 日韩大码丰满熟妇| 久久精品亚洲精品国产色婷小说| 90打野战视频偷拍视频| 熟女少妇亚洲综合色aaa.| 男人舔女人下体高潮全视频| 亚洲欧美激情综合另类| 国产精品久久久久久亚洲av鲁大| 久99久视频精品免费| 国产午夜福利久久久久久| 日韩精品免费视频一区二区三区| 亚洲欧美精品综合久久99| 亚洲国产精品999在线| 天堂动漫精品| 欧美一级a爱片免费观看看 | 欧美久久黑人一区二区| 午夜福利在线在线| 日韩大码丰满熟妇| 麻豆成人av在线观看| 嫁个100分男人电影在线观看| 亚洲国产日韩欧美精品在线观看 | 白带黄色成豆腐渣| cao死你这个sao货| 色av中文字幕| 亚洲片人在线观看| 法律面前人人平等表现在哪些方面| 亚洲 欧美 日韩 在线 免费| 黄片大片在线免费观看| 免费无遮挡裸体视频| 搡老妇女老女人老熟妇| 日韩精品中文字幕看吧| 狠狠狠狠99中文字幕| 曰老女人黄片| 亚洲国产欧美一区二区综合| 黄色成人免费大全| 在线观看一区二区三区| 日韩欧美在线二视频| 草草在线视频免费看| 成人亚洲精品av一区二区| 村上凉子中文字幕在线| 老司机午夜福利在线观看视频| 啦啦啦免费观看视频1| 18禁黄网站禁片午夜丰满| 欧美又色又爽又黄视频| 亚洲av熟女| 精品福利观看| 18禁裸乳无遮挡免费网站照片| 在线观看66精品国产| 欧美日韩乱码在线| 久久 成人 亚洲| 露出奶头的视频| 美女扒开内裤让男人捅视频| 国产91精品成人一区二区三区| 九色国产91popny在线| 哪里可以看免费的av片| 午夜精品一区二区三区免费看| 19禁男女啪啪无遮挡网站| 国产欧美日韩一区二区精品| 亚洲专区中文字幕在线| 国产精华一区二区三区| 三级国产精品欧美在线观看 | 给我免费播放毛片高清在线观看| 老司机靠b影院| 三级毛片av免费| 国产高清视频在线播放一区| 中文字幕精品亚洲无线码一区| 国产三级在线视频| 精品午夜福利视频在线观看一区| 国产高清激情床上av| 午夜久久久久精精品| 波多野结衣高清作品| x7x7x7水蜜桃| 在线视频色国产色| 午夜成年电影在线免费观看| 在线观看www视频免费| 欧美日韩福利视频一区二区| 神马国产精品三级电影在线观看 | 国产精品久久久av美女十八| 欧美zozozo另类| 日韩中文字幕欧美一区二区| 成人av在线播放网站| 亚洲最大成人中文| 国模一区二区三区四区视频 | 国产精品综合久久久久久久免费| 在线看三级毛片| 12—13女人毛片做爰片一| 老司机午夜十八禁免费视频| 亚洲国产精品999在线| 午夜成年电影在线免费观看| 丰满人妻一区二区三区视频av | 亚洲片人在线观看| 亚洲欧洲精品一区二区精品久久久| 老汉色av国产亚洲站长工具| 在线国产一区二区在线| 我要搜黄色片| 久久久久国产精品人妻aⅴ院| 成人午夜高清在线视频| 国产精品亚洲一级av第二区| 久99久视频精品免费| 身体一侧抽搐| 国产熟女午夜一区二区三区| 午夜福利在线在线| 久久久久九九精品影院| 18禁观看日本| 亚洲第一欧美日韩一区二区三区| 国产视频一区二区在线看| 午夜福利视频1000在线观看| 成人国产一区最新在线观看| 午夜精品久久久久久毛片777| 日韩欧美 国产精品| 国产成人一区二区三区免费视频网站| 国产精品久久久av美女十八| 中文字幕最新亚洲高清| 久久久国产欧美日韩av| 精品久久久久久久久久久久久| 亚洲熟妇熟女久久| 成人永久免费在线观看视频| 欧美在线一区亚洲| 欧美三级亚洲精品| 国产av又大| 国产精品影院久久| 亚洲av电影不卡..在线观看| 18禁国产床啪视频网站| 丁香六月欧美| 成在线人永久免费视频| 精品国产乱子伦一区二区三区| 国产一区二区三区在线臀色熟女| 亚洲色图av天堂| 久久久久国内视频| 麻豆成人av在线观看| 18禁黄网站禁片午夜丰满| 成人三级黄色视频| 最新美女视频免费是黄的| 国产爱豆传媒在线观看 | 久久亚洲精品不卡| 99久久国产精品久久久| 成人三级黄色视频| 成人18禁高潮啪啪吃奶动态图| 90打野战视频偷拍视频| 国产伦在线观看视频一区| videosex国产| 激情在线观看视频在线高清|